Zoran Zdraveski sold $952k of TCRX
See Remarks at TScan Therapeutics, Inc.. 164,686 shares at an average of $5.78, traded Aug 23, 2024, filed Aug 27, 2024.
Score components
- +15RoleOfficer
- +24Trade size$952k at market
- +20Share of holdings soldSold 97% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -10.1%, 3m -16.1%, 6m -62.9%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-24-101161, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 23, 2024 | MOption exercise Voting Common Stock | +54,895 | $4.85 | $266k | 67,111 | Aug 27, 2024 |
| Aug 23, 2024 | MOption exercise Voting Common Stock | +25,000 | $3.27 | $82k | 92,111 | Aug 27, 2024 |
| Aug 23, 2024 | MOption exercise Voting Common Stock | +13,125 | $1.81 | $24k | 105,236 | Aug 27, 2024 |
| Aug 23, 2024 | MOption exercise Voting Common Stock | +64,166 | $2.49 | $160k | 169,402 | Aug 27, 2024 |
| Aug 23, 2024 | SOpen-market sale Voting Common Stock | -164,686 | $5.78 | $952k | 4,716 | Aug 27, 2024 |
| Aug 23, 2024 | MOption exercise Stock Option (Right to Buy)derivative | -54,895 | $0.00 | $0 | 30,105 | Aug 27, 2024 |
| Aug 23, 2024 | MOption exercise Stock Option (Right to Buy)derivative | -25,000 | $0.00 | $0 | 25,000 | Aug 27, 2024 |
| Aug 23, 2024 | MOption exercise Stock Option (Right to Buy)derivative | -13,125 | $0.00 | $0 | 21,875 | Aug 27, 2024 |
| Aug 23, 2024 | MOption exercise Stock Option (Right to Buy)derivative | -64,166 | $0.00 | $0 | 365,834 | Aug 27, 2024 |
Related signals
Other insiders at TScan Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 36Weak | TCRXbuy TScan Therapeutics, Inc. | Lynx1 Capital Management LP owner | $146k 161,801 shares | +2% | |
| 46Moderate | TCRXbuy TScan Therapeutics, Inc. | Lynx1 Capital Management LP owner | $3.1M 2,588,794 shares | +48% | |
| 28Weak | TCRXbuy TScan Therapeutics, Inc. | Lynx1 Capital Management LP owner | $386k 131,800 shares | +3% | |
| 2Weak | TCRXbuy TScan Therapeutics, Inc. | Lynx1 Capital Management LP owner | $4,114 947 shares | +0% | |
| 36Weak | TCRXbuy TScan Therapeutics, Inc. | Barbara Klencke director | $26k 5,000 shares | +13% | |
| 36Weak | TCRXbuy TScan Therapeutics, Inc. | Barbara Klencke director | $56k 10,000 shares | +33% | |
| 52Moderate | TScan Therapeutics, Inc. | Timothy J Barberich director | $142k 29,147 shares | +77% | |
| 38Weak | TScan Therapeutics, Inc. | Barbara Klencke director | $25k 5,000 shares | +20% | |
| 46Moderate | TCRXbuy TScan Therapeutics, Inc. | Brian M. Silver Chief Financial Officer | $9,217 6,000 shares | +22% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.